Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108)

Karoly Szepeshazi, Andrew V. Schally, Gunhild Keller, Norman L. Block, Daniel Benten, Gabor Halmos, Luca Szalontay, Irving Vidaurre, M. Jászberényi, Ferenc G. Rick

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Many bladder cancers progress to invasion with poor prognosis; new therapeutic methods are needed. We developed a cytotoxic LH-RH analog, AN-152 (AEZS-108) containing doxorubicin (DOX), for targeted therapy of cancers expressing LHRH receptors. We investigated the expression of LH-RH receptors in clinical bladder cancers and in HT-1376, J82, RT-4 and HT-1197 human bladder cancer lines. The effect of analog, AN-152, on growth of these tumor lines xenografted into nude mice was analyzed. Using molecular and functional assays, we also evaluated the differences between the effects of AN-152, and DOX alone. We demonstrated the expression of LH-RH receptors on 18 clinical bladder cancers by immunohistochemistry and on four human urinary bladder cancer lines HT-1376, J82, RT-4 and HT-1197 by Western blotting and binding assays. AN-152 powerfully inhibited growth of these bladder cancers in nude mice. AN-152 exerted greater effects than DOX and was less toxic. DOX activated strong multidrug resistance mechanisms in RT-4 and HT-1197 cancers, while AN-152 had no or less such effect. PCR assays and in vitro studies revealed differences in the action of AN-152 and DOX on the expression of genes involved in apoptosis. These results suggest that targeted cytotoxic LH-RH analog, AN-152 (AEZS-108), should be examined for treatment of patients with LH-RH receptor positive invasive bladder cancers.

Original languageEnglish
Pages (from-to)686-699
Number of pages14
JournalOncotarget
Volume3
Issue number7
Publication statusPublished - Jul 2012

Fingerprint

Investigational Therapies
Urinary Bladder Neoplasms
Gonadotropin-Releasing Hormone
Doxorubicin
LH Receptors
Nude Mice
lysine(6)-doxorubicin LHRH
LHRH Receptors
Neoplasms
Poisons
Multiple Drug Resistance
Growth
Therapeutics
Western Blotting
Immunohistochemistry
Apoptosis
Gene Expression
Polymerase Chain Reaction

Keywords

  • Cytotoxic
  • Doxorubicin
  • LH-RH receptor
  • Targeted therapy
  • Urinary bladder
  • Urothelial cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Szepeshazi, K., Schally, A. V., Keller, G., Block, N. L., Benten, D., Halmos, G., ... Rick, F. G. (2012). Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108). Oncotarget, 3(7), 686-699.

Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108). / Szepeshazi, Karoly; Schally, Andrew V.; Keller, Gunhild; Block, Norman L.; Benten, Daniel; Halmos, Gabor; Szalontay, Luca; Vidaurre, Irving; Jászberényi, M.; Rick, Ferenc G.

In: Oncotarget, Vol. 3, No. 7, 07.2012, p. 686-699.

Research output: Contribution to journalArticle

Szepeshazi, K, Schally, AV, Keller, G, Block, NL, Benten, D, Halmos, G, Szalontay, L, Vidaurre, I, Jászberényi, M & Rick, FG 2012, 'Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108)', Oncotarget, vol. 3, no. 7, pp. 686-699.
Szepeshazi K, Schally AV, Keller G, Block NL, Benten D, Halmos G et al. Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108). Oncotarget. 2012 Jul;3(7):686-699.
Szepeshazi, Karoly ; Schally, Andrew V. ; Keller, Gunhild ; Block, Norman L. ; Benten, Daniel ; Halmos, Gabor ; Szalontay, Luca ; Vidaurre, Irving ; Jászberényi, M. ; Rick, Ferenc G. / Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108). In: Oncotarget. 2012 ; Vol. 3, No. 7. pp. 686-699.
@article{5a16e3fa65744978ac57d51d792057b9,
title = "Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108)",
abstract = "Many bladder cancers progress to invasion with poor prognosis; new therapeutic methods are needed. We developed a cytotoxic LH-RH analog, AN-152 (AEZS-108) containing doxorubicin (DOX), for targeted therapy of cancers expressing LHRH receptors. We investigated the expression of LH-RH receptors in clinical bladder cancers and in HT-1376, J82, RT-4 and HT-1197 human bladder cancer lines. The effect of analog, AN-152, on growth of these tumor lines xenografted into nude mice was analyzed. Using molecular and functional assays, we also evaluated the differences between the effects of AN-152, and DOX alone. We demonstrated the expression of LH-RH receptors on 18 clinical bladder cancers by immunohistochemistry and on four human urinary bladder cancer lines HT-1376, J82, RT-4 and HT-1197 by Western blotting and binding assays. AN-152 powerfully inhibited growth of these bladder cancers in nude mice. AN-152 exerted greater effects than DOX and was less toxic. DOX activated strong multidrug resistance mechanisms in RT-4 and HT-1197 cancers, while AN-152 had no or less such effect. PCR assays and in vitro studies revealed differences in the action of AN-152 and DOX on the expression of genes involved in apoptosis. These results suggest that targeted cytotoxic LH-RH analog, AN-152 (AEZS-108), should be examined for treatment of patients with LH-RH receptor positive invasive bladder cancers.",
keywords = "Cytotoxic, Doxorubicin, LH-RH receptor, Targeted therapy, Urinary bladder, Urothelial cancer",
author = "Karoly Szepeshazi and Schally, {Andrew V.} and Gunhild Keller and Block, {Norman L.} and Daniel Benten and Gabor Halmos and Luca Szalontay and Irving Vidaurre and M. J{\'a}szber{\'e}nyi and Rick, {Ferenc G.}",
year = "2012",
month = "7",
language = "English",
volume = "3",
pages = "686--699",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "7",

}

TY - JOUR

T1 - Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108)

AU - Szepeshazi, Karoly

AU - Schally, Andrew V.

AU - Keller, Gunhild

AU - Block, Norman L.

AU - Benten, Daniel

AU - Halmos, Gabor

AU - Szalontay, Luca

AU - Vidaurre, Irving

AU - Jászberényi, M.

AU - Rick, Ferenc G.

PY - 2012/7

Y1 - 2012/7

N2 - Many bladder cancers progress to invasion with poor prognosis; new therapeutic methods are needed. We developed a cytotoxic LH-RH analog, AN-152 (AEZS-108) containing doxorubicin (DOX), for targeted therapy of cancers expressing LHRH receptors. We investigated the expression of LH-RH receptors in clinical bladder cancers and in HT-1376, J82, RT-4 and HT-1197 human bladder cancer lines. The effect of analog, AN-152, on growth of these tumor lines xenografted into nude mice was analyzed. Using molecular and functional assays, we also evaluated the differences between the effects of AN-152, and DOX alone. We demonstrated the expression of LH-RH receptors on 18 clinical bladder cancers by immunohistochemistry and on four human urinary bladder cancer lines HT-1376, J82, RT-4 and HT-1197 by Western blotting and binding assays. AN-152 powerfully inhibited growth of these bladder cancers in nude mice. AN-152 exerted greater effects than DOX and was less toxic. DOX activated strong multidrug resistance mechanisms in RT-4 and HT-1197 cancers, while AN-152 had no or less such effect. PCR assays and in vitro studies revealed differences in the action of AN-152 and DOX on the expression of genes involved in apoptosis. These results suggest that targeted cytotoxic LH-RH analog, AN-152 (AEZS-108), should be examined for treatment of patients with LH-RH receptor positive invasive bladder cancers.

AB - Many bladder cancers progress to invasion with poor prognosis; new therapeutic methods are needed. We developed a cytotoxic LH-RH analog, AN-152 (AEZS-108) containing doxorubicin (DOX), for targeted therapy of cancers expressing LHRH receptors. We investigated the expression of LH-RH receptors in clinical bladder cancers and in HT-1376, J82, RT-4 and HT-1197 human bladder cancer lines. The effect of analog, AN-152, on growth of these tumor lines xenografted into nude mice was analyzed. Using molecular and functional assays, we also evaluated the differences between the effects of AN-152, and DOX alone. We demonstrated the expression of LH-RH receptors on 18 clinical bladder cancers by immunohistochemistry and on four human urinary bladder cancer lines HT-1376, J82, RT-4 and HT-1197 by Western blotting and binding assays. AN-152 powerfully inhibited growth of these bladder cancers in nude mice. AN-152 exerted greater effects than DOX and was less toxic. DOX activated strong multidrug resistance mechanisms in RT-4 and HT-1197 cancers, while AN-152 had no or less such effect. PCR assays and in vitro studies revealed differences in the action of AN-152 and DOX on the expression of genes involved in apoptosis. These results suggest that targeted cytotoxic LH-RH analog, AN-152 (AEZS-108), should be examined for treatment of patients with LH-RH receptor positive invasive bladder cancers.

KW - Cytotoxic

KW - Doxorubicin

KW - LH-RH receptor

KW - Targeted therapy

KW - Urinary bladder

KW - Urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=84868626417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868626417&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 686

EP - 699

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 7

ER -